imbruvia
Janssen’s Imbruvica shows superiority in Phase 3 trials
June 4, 2019Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial
Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
